Ovarian cancer endpoints workshop
FDA and the American Society for Clinical Oncology, in conjunction with FDA's Oncologic Drugs Advisory Committee, will hold a public workshop on ovarian cancer endpoints April 26 at the Marriott Hotel in North Bethesda, Md. FDA plans to issue a guidance document from the workshop findings. The agency has previously held meetings on lung, colorectal, prostate and brain cancer endpoints (1"The Pink Sheet" Feb. 6, 2006, p. 15). [Editor's note: To 2watch a webcastor order a video/DVD of this or any other meeting, visit FDAAdvisoryCommittee.com.]...
You may also be interested in...
Progression free survival assessed at six months should be considered as a meaningful surrogate endpoint in evaluating primary brain tumor clinical trials for accelerated approval, a panel assembled by FDA agreed
A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.